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Abstract
Background: Observational epidemiological and biological data indicate clear synergies between Herpes simplex
virus type 2 (HSV-2) and HIV, whereby HSV-2 enhances the potential for HIV acquisition or transmission. In 2001,
the World Health Organization (WHO) launched a call for research into the possibilities of disrupting this cofactor
effect through the use of antiherpetic therapy. A WHO Expert Meeting was convened in 2008 to review the
research results. The results of the trials were mostly inconclusive or showed no impact. However, the WHO
syndromic management treatment guidelines were modified to include acyclovir as first line therapy to treat
genital ulcer disease on the basis of the high prevalence of HSV-2 in most settings, impact and cost-benefit of
treatment on ulcer healing and quality of life among patients.
Methods: This paper examines the process through which the evidence related to HIV–HSV-2 interactions
influenced policy at the international level and then the mechanism of international to national policy transfer,
with Ghana as a case study. To better understand the context within which national policy change occurs, special
attention was paid to the relationships between researchers and policy-makers as integral to the process of getting
evidence into policy. Data from this study were then collected through interviews conducted with researchers,
program managers and policy-makers working in sexual health/STI at the 2008 WHO Expert Meeting in Montreux,
Switzerland, and in Accra, Ghana.
Results: The major findings of this study indicate that investigations into HSV-2 as a cofactor of HIV generated the
political will necessary to reform HSV-2 treatment policy. Playing a pivotal role at both the international level and
within the Ghanaian policy context were ‘policy networks’ formed either formally (WHO) or informally (Ghana)
around an issue area. These networks of professionals serve as the primary conduit of information between
researchers and policy-makers. Donor influence was cited as the single strongest impetus and impediment to
policy change nationally.
Conclusions: Policy networks may serve as the primary driving force of change in both international context and
in the case of Ghana. Communication among researchers and policy-makers is critical for uptake of evidence and
opportunities may exist to formalize policy networks and engage donors in a productive and ethical way.
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The process by which evidence generated from research
is incorporated into policy (at both national and interna-
tional levels) and practice is not always well understood,
particularly in low income countries. While the domi-
nant discourse in public health calls for evidence based
policy —where evidence stands above local interests
[1,2] — numerous policy analysis based models empha-
size the importance of local context in shaping policy
change or the uptake of evidence itself [3,4]. The overall
purpose of this study was to evaluate the process of
incorporating evidence from international or national
research into both international and national policies/
guidelines, in order to tease out the critical elements
that determine likelihood of research uptake in these
two international and national contexts respectively.
This study focuses on case studies of incorporating
management of herpes simplex virus type-2 (HSV-2)
into genital ulcer disease (GUD) treatment guidelines at
the World Health Organization (WHO, international
level) and in Ghana (national level).
HSV-2 and HIV synergies
Sexual acquisition of infection with HSV-2 (and some-
times HSV type-1) causes genital herpes, a chronic, life-
long disease, which manifests itself by recurrent ulcer
episodes and frequent viral shedding on genital mucosal
surfaces. HSV-2 is one of the most common sexually
transmitted infections (STI) worldwide [5-7]. A number
of clinical, epidemiological and biological studies have
shown that HSV-2 is strongly associated with increased
rates of HIV acquisition [8,9], and viral shedding in
HSV-2/HIV co-infected individuals, thereby increasing
their infectious potential for transmission [10-13]. More-
over, HIV infection alters the natural history of HSV-2
infection and severely immune-suppressed co-infected
patients may experience more frequent, severe or pro-
longed symptomatic recurrences [14,15] as well as
increased frequency of HSV-2 genital shedding
[11,16-18], facilitating the sexual transmission of either
virus. These reciprocal and synergistic relationships
underscore the importance of controlling HSV-2 for
HIV prevention [15,19].
HSV-2 management: international guidelines
Acyclovir is an anti-herpetic drug that shortens the
duration of HSV-2 clinical episodes if taken early, and
prevents recurrences if taken over longer periods of
time. However, this antiviral cannot cure genital herpes.
I th a sb e e nu s e dw i d e l yi nh i g hi n c o m ec o u n t r i e sa n d
has a good safety and efficacy profile [20]. WHO recom-
mends that low resource settings manage GUD and
other STI syndromes using the syndromic approach,
which provides presumptive treatment for all possible
treatable causes of the syndrome without the need to
carry out expensive or time-consuming diagnostic tests.
For a long time, the recommendation only included
treatment of curable bacterial infections, not viral infec-
tions, such as HSV-2. However, since HSV-2 has
become the most common GUD aetiology, and ulcers
caused by HSV-2 are not necessarily distinguishable
from other types of genital ulcers, particularly in HIV
positive individuals, WHO recommended in 2003 to
include acyclovir in the cocktail of drugs prescribed to
GUD patients, with the provision that it should be sup-
plied in settings where at least 30% of GUD are caused
by HSV-2 [21]. Few nations have this country-level data.
Moreover, there has been great reluctance in resource-
limited countries to treat HSV-2 as it is perceived to be
a self-limiting disease (at least in immuno-competent
individuals), treatment is not curative as episodes are
typically recurrent, there is a lack of awareness among
providers and a lack of access to anti-herpetic drugs at
the lower echelons of health care systems.
Prior to the addition of acyclovir to the management
guidelines, WHO had convened a meeting of interna-
tional researchers in 2001 to examine the role of herpes
on the HIV epidemic in developing countries [22]. The
meeting resulted in a call for research into the possibi-
lity of disrupting the observed co-factor effect of HSV-2
with the use of anti-herpetic therapy. Randomized con-
trolled trials were set up in Asia, sub-Saharan Africa,
Latin America and the United States to determine the
impact of either short-term episodic treatment of genital
ulcers or suppressive HSV therapy taken daily over sev-
eral months, and included HIV-infected and uninfected
populations. While the trials were in progress, the Glo-
bal Strategy for the Prevention and Control of STIs
(2006-2015) [23] was adopted at the World Health
Assembly in Geneva in June 2006. The Strategy called,
inter alia, for greater control of HSV-2 infection. By
April 2008, all but one trial had come to an end. The
results of the trials, as well as other biological, modeling
and economic analyses, were presented at a WHO
Expert Meeting in Montreux, Switzerland, which
informed the revision of the International STI Treat-
ment Guidelines.
The research found that 1) HSV-2 episodic therapy
was marginally beneficial in some, but not all patient
groups and settings, in terms of ulcer healing and reduc-
tion of HIV levels in the genital tract [24-26]; 2) HSV-2
suppressive therapy did not appear to prevent HIV
acquisition in two large trials [27,28]; 3) HSV-2 suppres-
sive therapy generally decreased HIV levels in plasma
and genital secretions in most studies [10,13,29-33]; but
4) this was not enough to decrease HIV transmission
between partners in HIV serodiscordant couples [34]
(this final landmark study ended one year after the
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Despite these globally disappointing results, a recom-
mendation was made during the Expert Meeting to
modify the WHO GUD syndromic management guide-
lines to include anti-herpetic therapy in the syndromic
management cocktail, without a prevalence threshold.
The decision was based on high HSV-2 prevalence
among GUD patients in all settings, clinical benefits to
those treated, and a potentially favorable cost-benefit
profile. Addition of acyclovir was found to increase the
number of ulcers correctly treated thereby reducing the
cost per ulcer treated, even when not taking into
account the potential for for loss of productivity due to
herpetic outbreaks and the increased rate of HIV acqui-
sition among HSV-2 positive individuals [35].
Ghanaian national policy
At the time of this study in July 2008, acyclovir was
available in Ghana but only prescribed in the private
s e c t o r .M e a n w h i l e ,G h a n aw a s still employing the pre-
2003 WHO GUD syndromic management guidelines
which did not include acyclovir [36]. Select physicians,
t h o s ew i t hm o r er e s o u r c e s ,o c c a s i o n a l l yg a v ea c y c l o v i r
as part of their treatment for GUD, but this was a rare
occurrence. Ghanaian health officials cited competing
health priorities and the chronic nature of herpes as
obstacles to guideline changes, despite the quality of life
argument to herpes suppression and the potential bene-
fit to Ghanaian workforce productivity.
Methods
The objectives of this study were: (1) to evaluate the
process by which findings of trials into the synergy
between HSV-2 and HIV on GUD influenced guidelines
formulated by the WHO, and (2) to investigate the pol-
icy transfer process from international guideline formu-
lation to policy development in Ghana. Both of these
policy change mechanisms have been investigated based
on theoretical frameworks of the policy process and the
ways evidence may be taken up into policy. Also under
examination was the relationship between research con-
ducted locally (within Ghana) and national policy devel-
opment, paying special attention to the Ghanaian policy
context in an effort to better understand the climate
within which policy change occurs at a national level.
A first set of in-depth interviews (n=11) was con-
ducted informally with attendees of the WHO Expert
Meeting to update the GUD syndromic management
guidelines in Montreux, Switzerland, in April 2008.
Interviewees included senior WHO officials, WHO pro-
gram staff and researchers from across the globe. Oral
consent was obtained based on conditions of anonymity
and all interviews were conducted by a single inter-
viewer (HB). A second set of interviews (n=8) was
conducted formally with high-ranking government offi-
cials, leaders in the non-profit public health sector and
distinguished researchers all working in the field of sex-
ual and reproductive health, in Accra, Ghana, during
July 2008. Interviews were conducted by the same inter-
viewer (HB) in the presence of a senior Ghanaian STI
researcher (YAS). Written consent was obtained from
all interviewees. Interview questions were scripted and
strictly adhered to for consistency. Interviews were con-
ducted in English, tape-recorded and transcribed. The
data from both sets of interviews were analyzed based
on trend analysis. With a fairly small number of inter-
viewees at the two sites, it was possible to complete a
manual trend analysis by comparing the transcribed
interviewee responses in order to identify the prevailing
themes.
Selection of case study
This research was commissioned by the DFID-funded
Research Project Consortium (RPC) on Research and
Capacity Building in Sexual & Reproductive Health and
HIV in Developing Countries. Members of the RPC
were personally involved in many of the HSV-HIV trials,
including one conducted in Ghana [18,24] and they pre-
sented their findings at the Montreux meeting. The
Ghana trial results had also been presented earlier (June
2006) to national stakeholders in Ghana, but no change
in management guidelines was introduced then,
although it was found that HSV-2 accounted for over
50% of genital ulcers in Ghana, thereby highlighting its
public health importance [18]. The link to HIV also
influenced selection of the case study, as international
attention paid to HIV prevention and care in recent
years has been noted for creating a ‘policy window’ for
change in relation to the treatment of potential cofactor
infections, particularly in parts of Africa which are
greatly affected by the HIV epidemic [37].
Theoretical frameworks for the evidence-policy interface
There are many theories about the way in which evi-
dence generated from research is (or is not) incorpo-
rated into policy. The presence or expectation of an
evidence base to a policy or practice has become com-
monplace, specifically in the public health field which
tends to value evidence above ideological concerns [1,2].
However, insights into evidence and policy from a policy
analysis perspective recognize the importance of other
elements beyond the evidence itself as influential in
shaping how research findings get taken up in decision
making [38]. These models point to the importance of
multiple competing political factors shaping policy-mak-
ing [39], and often emphasize the links between key net-
works connecting researchers and policy makers [3]. In
this case study, exploration has been dissected into
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work to guide research and analysis: (1) evidence to pol-
icy theories, (2) actors and policy networks, and (3)
international to national policy transfer theories.
Evidence to policy theories
A number of frameworks have been proposed to explain
the research-policy interface. One of the most straight-
forward is the linear/rationalist model, which views pol-
icy change as pragmatic problem-solving with evidence
providing the basis for policy decisions [40]. In this con-
ceptualization, reviewing relevant evidence is all that is
needed to guide policy to a correct decision. When evi-
dence is not used as it should be, the problem is seen as
a technical one – a breakdown in communication
between the ‘two-worlds’ of researchers and policy
makers. The ‘two-worlds’ view [41] particularly focuses
on the different needs and expectations of researchers
and policy-makers. The world of researchers is depicted
as scientifically complex and places an emphasis on pro-
cess and purity of findings. The world of policy-makers,
on the other hand, wants certainty, timeliness and sim-
plicity. Lomas describes the tension as “decision-makers
accuse researchers of irrelevant, poorly communicated
‘products’; researchers accuse decision-makers of politi-
cal expediency that results in irrational outcomes” [42].
This rationalist view, however, strikingly ignores poli-
tics and political interest in the research to policy conti-
nuum. Political theorists emphasize the political space,
and typically point to the multiple competing elements
which can influence policy makers. Lin, for instance,
refers to three competing ‘rationalities’ in decision mak-
ing –‘ technical’ rationalities (such as those driven by evi-
dence) must compete with ‘political’ and ‘cultural’
rationalities (demands) [38]. Other authors similarly
e m p h a s i z et h a tp o l i c ym a k i n gi sn o tas i m p l ep o i n to f
decision making, but one which occurs in a broader con-
text (with broader issues influencing decision making).
From these perspectives, the nature of the policy mak-
ing body and its competing demands may be highly
relevant to shaping the uptake of research into policy.
International organizations, such as the WHO, are
expected to have fewer competing political influences
and a more homogenous cultural view of the impor-
tance of evidence in shaping health policy. Finally, the
context of policy making would be insulated from many
other issues due to the WHO’sn a r r o wf o c u so nh e a l t h -
care. National governments, however, may show great
variety in all these issues. The importance of research
evidence in competition with other demands on policy
makers, and the changing contexts and importance of
health decisions may be very locally specific, and play a
g r e a tr o l ei ns h a p i n gt h eu p t a k eo fe v i d e n c ef o ra n y
given case.
Actors and policy networks
Many health policy and research-to-policy theories,
place actors and networks of actors centrally in explain-
ing policy change [3,4], highlighting the importance of
networks in influencing public policy outcomes [43].
Networks can take various forms in these works, includ-
ing ‘epistemic communities’ of scientific or disciplinary
experts who have access to policy-makers, or cross-cut-
ting ‘policy networks’ linking actors representing gov-
ernment, economic and professional interests involved
in a specific decision making structure [43,44]. Haas in
particular contends that it is the informal networks that
exist among and around actors that are key to bridging
the research-policy gap at all levels [45]. Information
flows through these communities freely, and if the com-
munity includes policy-makers or other influential per-
sons (as well as researchers, or other custodians of
evidence), the community itself can serve to exert pres-
sure on those policy-makers, thus skirting tiresome
bureaucratic channels [45]. Haas notes that policy com-
m u n i t i e si ng e n e r a lm a yb ed i f f i c u l tt ot r a c e ,s ot h e i r
influence in policy development may be underestimated.
In international organizations such as the WHO, how-
ever, these networks are much more evident and are
often institutionally structured into decision making
processes. One would expect to see clear and regular
contact between researchers and decision makers in
such an institution. At national levels, however, the rela-
tionships may be more variable – changing over time
and according to the nature of the issue. As such, inves-
tigation is needed at the national level to understand
h o wa n dw h e ns u c hn e t w o r k sp l a yar o l ei np o l i c y
change.
The RAPID (Research and Policy in Developing Coun-
tries) programme of the Overseas Development Institute
reviewed 50 case studies to examine these processes.
Their conceptual framework contends that there is an
integral interconnectivity between the political context
(political structures/processes, institutional pressures,
prevailing concepts, policy streams and windows), the
evidence (credibility, methods, relevance, use, how the
message is packaged and communicated), and links
(between policy-makers and other stakeholders, relation-
ships, voice trust, networks, the media and other inter-
mediaries) [46]. This all-inclusive analysis then places
these three factors, or overarching themes, in the con-
text of external influences, including economic and cul-
tural influences among others [46]. The degree to which
each of the factors takes center stage in terms of driving,
impeding or simply engaging in research-to-policy is
fluid throughout the process and highly case-specific;
however, networks of actors remain central to the land-
scape of change in every instance.
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The complexities of policy making at a national level
can further be illustrated by the processes in which
international recommendations are transferred to the
local level. Rather than a simple process of copying
higher level guidelines, often a more iterative process
exists where pieces of information are taken up, inter-
preted and adapted [47]. This process can be illustrated
through specific country case studies. Based on a study
of policy transfer of tuberculosis and STI management
in Mozambique [48] for instance, it was found that poli-
cies do not appear to follow one transfer mechanism,
but rather, policy formulation requires many “loops”
that rely on both bottom-up and top-down dissemina-
tion. According to another global perspective case study
of STI management [49], international-to-national policy
transfer results from a process described by Kingdon’s
famous ‘’streams” model which may be used to analyze
policy change at local, national and international levels
[50]. The model focuses on agenda setting and timing
as the key components to policy reform. The so-called
streams consist of (1) a problem stream – linked to
identification or recognition of problems, (2) a policy
stream – encompassing feasible policy solutions, and (3)
a politics stream – reflecting the political will to address
an issue [50]. A policy window is seen to occur when
these three streams ‘intersect’ in time. That is to say
when a problem is recognized, a solution is available,
and political will is strong enough. It is then that policy
reform is introduced. This window presents itself as the
focal point for researchers hoping to influence policy, or
the point at which evidence can be incorporated into
policy. This window of opportunity may be the result of
an organic process, but it may also be induced by well-
placed actors (known as ‘policy entrepreneurs’)w h o
recognize when time might be ripe for policy change
[50]. Network theorists also see networks as playing key
roles in international to national policy transfer [44],
and it can be conceptualized that these policy entrepre-
neurs typically need to be members of important policy
networks.
As a whole, then, there are numerous theories and
models of the process of policy change, and of the
uptake of research into policy. Those often used in pub-
lic health discourse tend to see getting research into
policy as a technical exercise— bridging the gap between
evidence and policy circles. Those deriving from policy
analysis perspectives, however, typically emphasize the
complexity of factors influencing decisions and decision-
makers. While diverse, the core of many of these the-
ories have to do with political issues, competing inter-
ests, and policy processes that only enable change when
particular conditions are met. In both sets of views, key
actors and networks play important roles connecting
researchers to policy-makers, pushing technical consid-
erations in debates, and identifying windows of opportu-
nity for policy change. Our study uses these insights to
compare the evidence to policy process in the sexual
health/STI field in both international (WHO) and
national (Ghana) contexts.
Results
Influencing international policy: the WHO GUD syndromic
management guidelines
Common among all Montreux interviewees is the belief
that a ‘policy window’ was a key determinant for the
inclusion of acyclovir in the GUD syndromic manage-
ment guidelines. As suggested earlier, it would not be
illogical to assume that the power of observational data
alone may be more influential in the context of the
WHO than in a national setting. It was not, however,
found to be sufficient. One policy-maker in Montreux
noted that “evidence is not sufficient: facts are facts, per-
ception is reality” and went on to say that “even if there
is evidence for a change in policy, it will not matter
until it is perceived that it should matter.” This indicates
that even in a context such as the WHO which focuses
on best practices in health, there are multiple factors
affecting the uptake of evidence. In line with Kingdon’s
T h r e eS t r e a m sM o d e l ,t h eo b s e r v a n c eo fas y n e r g y
between HIV and HSV-2 (problem stream) combined
with the international attention and donor focus on
HIV (politics stream) served to push HSV-2 on to the
international agenda. As stated by one WHO policy-
maker, “without these trials [into disrupting the co-fac-
tor effect between herpes and HIV] we would not even
be discussing herpes or thinking about making acyclovir
standard practice.” It was highly anticipated that the
trial results would provide evidence for an effective
intervention (policy stream), thereby satisfying Kingdon’s
prerequisites for the creation of a policy window. Inter-
viewees agreed that the momentum generated through
the potential to impact HIV transmission and acquisi-
tion through addressing HSV-2 allowed for inclusion of
acyclovir in the guidelines despite the trials’ findings
showing no impact on HIV transmission: it provided a
platform to those who sought to “treat herpes for herpes
sake,” commented one researcher.
As noted above, the initial impetus for policy change
with regards to HSV-2 was a bottom-up process in which
observational data in a few countries triggered interna-
tional investigation. Once evidence of a synergy between
the two viruses had accumulated through in-country
observational data and some international reviews and
meta-analyses, the ‘policy network’ of researchers, pro-
gram managers and policy-makers who were to later
comprise the 2008 WHO Expert Review took it upon
themselves to drive the agenda. Researchers and policy-
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2001 call for research and many of these same research-
ers either ran or advised on the individual trials. These
same policy-makers then played a central role in passing
t h eG l o b a lS t r a t e g yf o rt h eP r e v e n t i o na n dC o n t r o lo f
STI at the World Health Assembly [23], thereby priming
the stage for policy change with a renewed international
focus on STIs. When questioned on this club-like camar-
aderie among key contributors to the Montreux meeting,
one researcher answered, “well, many of us were here [at
t h eW H O ]f o rt h e[ d e v e l o p m e n to ft h e ]f i r s t[ s y n d r o m i c
management] guidelines.”
Although in many respects, at the international level,
researchers and policy-makers worked in tandem, the
existence of a divide between the so called ‘two-worlds’
was plainly evident through the course of the Montreux
meeting. There, program managers also played a role in
the decision-making process. All three groups wanted
something different out of the research findings:
researchers were interested in the statistical significance
of the findings and implications for further studies; pol-
icy-makers wanted a recommendation for policy-change;
and program managers wanted to be able to supply the
communities they served with acyclovir based on the
observed disease burden. One program manager voiced
his/her concern directly to the researchers: “Are you
going to make any recommendations? All I hear is the
need for more research.” On this point, policy-makers
agreed. All non-researchers interviewed were frustrated
with the researchers for not getting to the bottom of
“the so-what factor” as one interviewee termed it.
Mechanisms of getting research into policy in Ghana
According to WHO interviewees, it often takes as long
as two years, or sometimes even longer, for changes in
treatment guidelines to be disseminated through
national governments to practitioners working in low
income countries. One WHO policy maker predicted:
“we will be lucky if this [change in the syndromic man-
agement treatment guidelines] even gets to the [WHO]
country offices in two years time.” For this reason, Gha-
naian interviewees were asked to speculate on the likely
process for policy change in regards to the HSV-2 treat-
ment based on their extensive experience with previous
changes in WHO STI treatment guidelines. Donors’
stringent funding eligibility requirements were repeat-
edly cited as the single strongest impetus for policy
change. One program manager interviewed stated,
“where there is money, we manage to get something
done, otherwise we have competing priorities.” This is
not surprising as Ghana’s health sector, particularly in
the area of prevention, is heavily dependent on foreign
aid. Therefore, donors’ interests may often dominate
research agendas, programming decisions, and policy,
simply due to their financial power. Another intervie-
wee, a researcher, commented, “Ia mn o ts u r et ow h a t
extent we or any developing country owns the research
agenda … people come from outside and say, ‘we want
to look at this and we have this money.’ There is a lot
of frustration and a lot of brain drain.” This domination
by donor interests can therefore work in two ways: (1) if
a donor pays attention to a particular issue it gains
national importance, and (2) if a donor does not empha-
size an issue, it may be ignored nationally to accommo-
date a competing priority. Program managers and even
some policy-makers felt that they were unable to act
upon research findings, even in cases where it was clear
that change would be beneficial because “we don’th a v e
t i m ea n dw em u s tb er e s p o n s i v et od o n o r sf i r s to rw e
cannot do anything at all,” said one policy maker.
According to all interviewees, policy-makers [in Ghana]
often give more weight to international research results
over national research due to the wider dissemination of
research findings and the potential influence on donor
funding. The policy-makers went further to contend
that, in the case of HSV-2 treatment, without clear evi-
dence that acyclovir disrupts the cofactor effect between
HSV-2 and HIV, they did not anticipate including acy-
clovir in the syndromic management cocktail, unless
there was funding attached both for procurement and
for drug delivery. Because the trial results did not indi-
cate that HSV therapy was an effective HIV prevention
strategy, the same interviewees highly doubted that
donor organizations, many of which they feel were myo-
pically HIV-focused, would make herpes treatment a
priority.
The researchers all felt that there was great difficulty
in attracting the policy-makers’ attention to this issue:
“there is so much going on, it sometimes doesn’t matter
how loud your voice is.” T h em a j o r i t yo fr e s e a r c h e r s
interviewed went further to predict that this is a case in
which formal policy change will lag behind practice and
that acyclovir might be used because of the high preva-
lence of HSV-2 among GUD cases, provided the drugs
can be made available. Practice was also a precursor to
policy reform for the initial adoption of STI syndromic
management itself [51], indicating that in the interest of
expediency of delivery, it may be the case that practice
may often precede national STI policy reform [49].
Some argued that in the case of HSV-2, in private set-
tings and on a small scale, practice was already preced-
ing policy, as acyclovir is available and prescribed. As
noted earlier, acyclovir was not on the national essential
drugs list and so not available in the public sector.
This is not to say that Ghanaian policy reform is only
responsive to donors’ directives. Another mechanism
through which change may occur is if an influential
enough individual (a ‘policy entrepreneur’) who is either
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HIV Control Program, and, according to one Ghanaian
researcher, “who is well liked either within [the Ministry
of Health] or outside [in the community],” makes a
strong case for the change. This mechanism is particu-
larly effective for getting operational research findings
into policy. In order for a policy entrepreneur to bring
about change, however, all interviewees agreed that con-
ditions apply. The policy change must be seen to: (a)
save money in the long run, (b) be highly visible and
good for public relations, (c) be beneficial to the popula-
tion at no extra cost, or (d) have any extra costs covered
by donor agencies, and/or (e) have the potential to
attract additional donor funding. These conditions
essentially outline the prerequisites for generating politi-
cal will at the national level.
Ghana’s experience, unsurprisingly, pointed to the many
ways that key networks of actors – and links between
them– were essential to understanding the research to
policy process. Researchers interviewed mentioned their
friends in policy positions as being instrumental in the
researchers’ attempts to impact policy: “If I see something
n e e d st ob ed o n ea n di t ’s not, I call my friend,” said one
researcher. This dynamic constitutes a policy network, one
that links researchers with well placed individuals able to
influence policy. Based on the interviews, it appears that
w i t h i nt h e s en e t w o r k si ti so f t e nas i n g l ec h a m p i o no fa
cause (or policy entrepreneur) who carries the issue and
generates internal pressure, although this may not always
be the case. Many policy-makers and program managers
confirmed the existence of these communities. They spoke
of personal ties through either old friends or colleagues to
certain research groups and cited these ties as their main
taproot to the latest research. One policy-maker in Ghana
recommended, “We need to make these networks more
solid [as a mechanism for bringing research and policy
closer together].”
Discussion
According to the Montreux interviewees, the compara-
tively high profile of HIV generated the political will
necessary for HSV-2 to be brought on to the interna-
tional research agenda. This indicates that even within
the context of the WHO, which is comparatively immune
to the multiple competing priorities seen to impede
national policy reform, policy change still has political
elements. In order to address issues which receive little
political attention, linking to a larger, more popular issue
may be necessary in order to gain political traction. In
addition, there was a resounding call from policy-makers
and program managers for researchers to engage in help-
ing to bridge the divide between research and practice
through indicating the programmatic and policy rele-
vance of both their research and their findings.
On the Ghanaian national policy front, multiple com-
peting priorities appeared to influence the uptake of
research findings into national policy reform. Three
mechanisms emerged. The first is to bypass policy
reform. Many of the researchers in Ghana also have a
clinical practice. Therefore, the distance between
research and practice can be shortened, as compared to
the distance between research and policy. Bypassing pol-
icy as a rule will not, however, support provision of care
for all who need it. The second mechanism is orientated
towards policy reform and focuses on the central role of
actors in the national context. Both policy networks and
policy entrepreneurs (often working within this group),
were described as critical to bridging the gap between
research and policy. In the case of Ghana, policy net-
works are cited as the only functional communication
channel between researchers and policy-makers. A final
mechanism for influencing policy involves donors. At
the national level, donor attention to a particular issue,
or lack thereof, heavily influences the likelihood of pol-
icy reform. In the case of HSV-2, it was predicted that a
lack of donor attention combined with competing donor
priorities, would impede the inclusion of acyclovir in
national syndromic management guidelines.
Since completion of our study, further policy develop-
ment has occurred in Ghana. The prediction that lack
of donor interest would impede policy change proved
incorrect. This appears to be because of the influence of
a key policy network (linking both policy-makers and
researchers) who, in 2009, met at the National AIDS
Control Program to discuss implications from the find-
ings of the Ghanaian HIV/ HSV-2 trial. During the
course of the meeting, which included Ghanaian Gov-
ernment health officials, it was decided that acyclovir
should and would be added to national GUD treatment
policy. It is not clear how this meeting was convened or
who drove the agenda, however, what is evident is that
there was a network of interested and connected
researchers and policy-makers at the heart of the pro-
cess (Figure 1).
At the international level, there appears to be more
formalized networks of actors influential in WHO deci-
sions. The majority of individuals invited to attend the
Expert Meeting in Montreux are actually frequent advi-
sors to the WHO. In the case of STIs, this invitation
does not appear to extend well beyond the bounds of
the personalities present at the meeting, as evidenced by
the observation that the same individuals had been
involved in the various iterations of the STI syndromic
management guidelines development.
Conclusion
It becomes evident that in the case of HSV-2 and the
changes made to the GUD syndromic management
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between HIV and HSV-2 played a pivotal role in gener-
ating the political will neces s a r yf o rt h ec r e a t i o no fa
policy window. Policy networks and policy entrepre-
neurs emerged as playing recurrent important roles. It
appears that these communities and the actors that
comprise them may provide the primary impetus for
policy change, within both case study contexts. Evidence
alone emerged as unable to influence policy without the
engagement and alignment of multiple factors.
Based upon these research findings, there are several
follow-on recommendations for increasing the likelihood
of research uptake into policy/guidelines at both the
national and international levels in the field of STIs and
HIV. Within the WHO, it appears important to link
with existing priorities (if possible) in order to attract
attention to an otherwise marginalized issue. The entire
sexual health/STI research to policy continuum lives
within the apparent confines of the WHO STI policy
network. This is a formalized community and one that
is recognized for its contribution to policy change.
Researchers may wish to proactively target this network,
particularly in communicating the practical application
of their findings (the “so what factor” of their work).
Ideally, such communication would begin at the outset
of research work and continue throughout the duration
of any study, thereby building up to any potential
recommendations for change, and establishing legiti-
macy of the researchers to the network members when
their findings become available.
In the case of Ghana, the policy network is entirely
informal, and yet is still a powerful contender in affect-
ing policy change. The existence of this group presents
an opportunity to disseminate study findings and exert
pressure on policy-makers in an effective manner.
In this way, often difficult to reach policy-makers may
be included in research from the outset of a study,
instead of as an endpoint for the presentation of
Timeline of Relevant Events
•Acycloviraddedtotheessentialdrugslistforuseattheprimarycarelevel.
PostͲStudyUpdates
Figure 1 Timeline of Relevant Events.
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Page 8 of 10research findings. In this way, policy-makers may also
better understand the policy implications of research
findings particularly in the case of research conducted
locally. Also key to the national research-to-policy conti-
nuum are donors. Donor engagement around policy
change is a difficult issue. Donor power emerged as a
consistent theme in the Ghanaian case study, and there
is a high likelihood that this finding can be extrapolated
to other health areas and potentially other low-income
countries. The possibilities then for ethical donor
engagement in research-uptake at the national level, and
particularly in the case of research conducted locally,
deserves further study.
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